Get started
Author

JungAh Jung

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2012 · Andres Cervantes, Elena Elez, et al. · Clinical Cancer Research · 153
Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo‐Controlled Phase 3 Trial
2023 · Anita H. Clayton, Robert Lasser, et al. · American Journal of Psychiatry · 87
An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes
2014 · Stuart L. Goldberg, Pierre Fenaux, et al. · Leukemia Research Reports · 77
PDF
Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)
2011 · Jonathan Friedberg, Daruka Mahadevan, et al. · Blood · 45
Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study
2023 · Sagar V. Parikh, Scott T. Aaronson, et al. · Neuropsychopharmacology · 27
PDF
First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)
2015 · Owen A. O'Connor, Muhit Özcan, et al. · Blood · 25
Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor In Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS)
2010 · Stuart L Goldberg, Pierre Fenaux, et al. · Blood · 20
Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors
2015 · Gerald S. Falchook, Xiaofei Zhou, et al. · Drugs in R&D · 11
PDF
MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study.
2014 · Cristina Cruz Zambrano, Khaldoun Almhanna, et al. · Journal of Clinical Oncology · 9
Mln0264, an Investigational, First-In-Class Antibody-Drug Conjugate Targeting Guanylyl Cyclase C (Gcc): First-In-Human Study in Patients with Advanced Gastrointestinal Malignancies
2013 · Wells Messersmith, Khaldoun Almhanna, et al. · Annals of Oncology · 3
PDF
MLN0264, an investigational, first-in-class antibody-drug conjugate (ADC) targeting guanylyl cyclase C (GCC): Phase I, first-in-human study in patients (pts) with advanced gastrointestinal (GI) malignancies expressing GCC.
2013 · Khaldoun Almhanna, Wells A. Messersmith, et al. · Journal of Clinical Oncology · 3
Survival Instantaneous Log-odds Ratio from Empirical Functions
2007 · JungAh Jung, J. Wanzer Drane · The International Journal of Biostatistics · 2
Abstract B194: Phase 1 relative bioavailability study of a prototype oral solution (OS) formulation of the investigational Aurora A kinase (AAK) inhibitor alisertib (MLN8237) in reference to a powder-in-capsule (PIC) formulation in patients with advanced solid tumors.
2011 · Gerald S. Falchook, John Sarantopoulos, et al. · Molecular Cancer Therapeutics · 1
Supplementary Tables 1 - 4 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
PDF
Supplementary Methods from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
PDF
Supplementary Figure 2 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Supplementary Figure 3 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Supplementary Figure 5 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Supplementary Figure 4 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Supplementary Figure 1 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
PDF
Supplementary Tables 1 - 4 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Supplementary Methods from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Supplementary Figure 4 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
PDF
Supplementary Figure 1 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
Supplementary Figure 2 from Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
2023 · Andres Cervantes, Elena Elez, et al.
PDF
Works count: 29
Citation count: 463
H-index: 9
I10-index: 8
Year
Topic
Type